Depigmented-polymerised allergoids favour regulatory over effector T cells: enhancement by 1α, 25-dihydroxyvitamin D3
- Zoe L Urry1,
- David F Richards1,
- Cheryl Black1,
- Maria Morales2,
- Jerónimo Carnés2,
- Catherine M Hawrylowicz†1Email author and
- Douglas S Robinson†3Email author
© Urry et al.; licensee BioMed Central Ltd. 2014
Received: 30 October 2013
Accepted: 16 May 2014
Published: 29 May 2014
Allergen immunotherapy (SIT) is the only treatment for allergic disease capable of modifying disease long term. To reduce the risk of anaphylaxis from SIT, allergen-extracts have been modified by polymerisation with glutaraldehyde to reduce IgE binding. It is suggested that these allergoid extracts also have reduced T cell activity, which could compromise clinical efficacy. Effective SIT is thought to act through regulatory T cells (Tregs) rather than activation of effector T cells. There is no published data on the activity of modified extracts on Tregs.
We compared the capacity of modified (depigmented-polymerised) versus unmodified (native) allergen extracts of grass pollen and house dust mite to stimulate proliferation/cytokine production and to modulate Treg/effector T cell frequency in cultures of peripheral blood mononuclear cells (PBMC), from volunteers sensitised to both allergens in vitro. Depigmented-polymerised allergen extracts stimulated less proliferation of PBMC, and reduced effector cell numbers after 7 days in culture than did native extracts. However, the frequency of Foxp3+ Tregs in cultures were similar to those seen with native extract so that ratios of regulatory to effector T cells were significantly increased in cultures stimulated with depigmented-polymerised extracts. Addition of 1α, 25-dihydroxyvitamin D3 further favoured Treg, and reduced effector cytokine production, but not interleukin-10.
Depigmented-polymerised allergen extracts appear to favour Treg expansion over activation of effector T cells and this may relate to their demonstrated efficacy and safety in SIT. 1α, 25-dihydroxyvitamin D3 further reduces effector T cell activation by allergen extracts and may be a useful adjuvant for SIT.
KeywordsAllergen extract Depigmented-polymerised Immunotherapy Regulatory T cell Vitamin D
Specific allergen immunotherapy (SIT) is recommended for persistent allergic rhinoconjunctivitis and asthma resistant to pharmacotherapy, and is the only disease-modifying treatment in that benefit persists after stopping treatment [1, 2]. However, subcutaneous injection of immunotherapy (SCIT) extracts carries a risk of anaphylaxis, whilst sublingual therapy (SLIT) requires daily treatment over three years. One approach to reducing the risk of anaphylaxis with SCIT is to modify allergen extracts to reduce IgE binding . Such allergoids include extracts treated with acid (“depigmented”), prior to polymerisation with glutaraldehyde . These extracts showed efficacy in clinical trials for both birch and grass pollen-related allergic rhinitis, and house dust mite-related asthma [5–8]. In these studies and large observational series, side effects were minimal [5–9]. The resulting depigmented-polymerised (Depig-pol) allergen extracts are of very large molecular mass (0.5-3 MDa as opposed to less than 100 KDa for native allergen extracts), and have at least 50 times reduced IgE binding in vitro in competition assays and in vivo in skin prick testing [4, 10, 11]. Analysis of sequences obtained by enzymatic digestion of Depig-pol and native extracts suggests conservation of major allergen sequences for both dust mite and pollen extracts [10, 11], and in vivo immunogenicity studies show induction of IgG directed against the majority of major allergens upon treatment of patients with these extracts and in studies involving immunization of experimental animals [5–7, 11].
Whilst allergoids have reduced IgE binding (allergenicity) which may improve safety, it has also been suggested that they have reduced T cell stimulating activity (immunogenicity) which could compromise efficacy . Studies of T cell activity of allergoids in terms of proliferation of primary T cells, lines or clones, have suggested variable degrees of loss of ability to stimulate T cells, either generally or restricted to some epitopes [12–16]. However, the immunological efficacy of SIT most likely relates to induction of tolerance to allergens through interactions with regulatory T cells (Treg) . Studies with unmodified allergen extracts suggest increased numbers and activity of both CD4+CD25hiFoxp3hi T cells and IL-10 producing T cells after SIT treatment, together with induction of the IL-10-dependent antibody IgG4 . Thus expansion of Tregs may be a more relevant activity to assess for allergen extracts for SIT.
In order to improve efficacy, reduce dosing and improve safety of allergen immunotherapy a number of adjuvants have been examined. In particular, there is much current interest in 1α, 25-dihydroxyvitamin D3, which can expand both induced IL-10-producing and Foxp3+ Treg in vitro, and improved effects of immunotherapy in animal models [18–21]. Vitamin D status and/or treatment of human volunteers with vitamin D derivatives correlated with or increased Foxp3+ T cell frequency in the periphery  and the airway in asthmatics  and IL-10 producing Treg in the periphery .
Here we have examined the relative stimulation of effector and regulatory T cells in vitro by unmodified and depigmented-polymerised allergen extracts, together with the effects of 1α, 25-dihydroxyvitamin D3.
Depigmented-polymerised allergen extracts stimulate less T cell proliferation than native extracts, but similar cytokine production
Dermatophagoides pteronyssinus (HDM) Phleum pratense (Grass)
Proliferation for depigmented HDM and GRASS extracts was very similar to that seen for native extracts, but proliferation was signficantly less for Depig-pol extracts of both HDM and GRASS when compared to native unmodified extracts (Figure 1B and ref ). For this reason, further comparisons were between native and Depig-pol extracts.
Depigmented-polymerised allergen extracts expand regulatory T cells more than effector T cells in culture
Addition of 1α, 25-dihydroxyvitamin D3 to cultures further favours CD25hiFoxp3hiCD127lo T cells
These data suggest reduced proliferation and cytokine production (particularly IL-17 and IFNγ) by PBMC from atopic donors stimulated with Depig-pol extracts compared to native, unmodified allergen extracts for grass pollen and house dust mite. However, Depig-pol allergen extracts for grass pollen and HDM favoured expansion of regulatory T cells over effector T cells in vitro, and this balance was further tilted towards regulation by 1α, 25-dihydroxyvitamin D3. Thus Depig-pol allergen extracts may favour regulatory T cells over effector T cell activation, which might be expected to augment tolerance induction in SIT.
Several reports have previously examined T cell responses to allergoids [12–16]. All showed reduced proliferation of PBMCs stimulated with allergoid when compared to native allergen, and variable reductions in cytokine production. This difference in T cell proliferation between allergoid and native extract was suggested to vary with antigen presenting cell type, although this was not confirmed in a subsequent study [15, 16]. Analysis of responses of T cell lines and clones suggested variable loss of T cell epitopes in allergoid extracts compared to native extracts [13–15]. Our data also suggests reduced proliferation and effector cytokine production by PBMC stimulated by Depig-pol extracts compared with native extract, and these findings were confirmed by reduced expansion of cells with effector phenotype in Depig-pol stimulated cultures. We would argue that reduced activation and expansion of effector T cells by Depig-pol extracts will actually be beneficial in the context of SIT, where effector T cell activation may contribute to side effects. This is demonstrated most graphically for peptide therapy where small allergen peptides which did not cross link IgE nonetheless activated effector T cells and lead to isolated late asthmatic reactions in patients . We did not examine loss of T cell epitopes comparing Depig-pol extracts with native extracts, although previous mass spectroscopic analysis has suggested preservation of most major allergen sequences . Even if some T cell epitopes were lost during the depigmentation and polymerisation process, we would argue that the critical activity for tolerance induction is expansion of regulatory T cells that work in both antigen-specific and non-antigen specific fashion, as shown by linked suppression to cat major allergen Fel d 1 peptides not included in the experimental peptide immunotherapy treatment in an animal model .
Although Depig-pol extracts stimulated reduced effector T cell expansion and activation compared to native extracts, numbers of regulatory T cells were similar, so the ratio of regulatory to effector T cells in cultures stimulated with Depig-pol extracts was significantly higher than for native extract. Activation requirements for effector versus regulatory T cells are incompletely understood, but we would suggest that antigen-presenting cell processing of and activation by these molecules of vastly different mass may be relevant in the case of Depig-pol versus native extracts [10, 11].
Interestingly, our data both here and in previous studies  suggest that depigmented-polymerised extracts and 1α, 25-dihydroxyvitamin D3 both favour Foxp3hi T cells (by reducing expansion of effector T cells). Initial reports suggested that 1α, 25-dihydroxyvitamin D3 acted to expand IL-10 producing T cells . However, our recent data shows that 1α, 25-dihydroxyvitamin D3 can also expand Foxp3hi Tregs . The type of Treg emerging depended on the concentration of 1α, 25-dihydroxyvitamin D3 in cultures, and the cytokine milieu and essentially no co-expression of Foxp3 and IL-10 was observed, although both populations exhibited comparable suppressive activity [19, 20]. The present findings are in keeping with that data in that a relatively higher concentration favoured Foxp3hi Tregs (albeit 10-7 M here rather than 10-6 M in an anti-CD3 driven culture system), and in these conditions IL-10 producing T cells were not detected (data not shown). Our previous report suggested that the major effect of 1α, 25-dihydroxyvitamin D3 was to suppress proliferation of effector T cells and maintain Foxp3 expression by regulatory T cells: our current data agrees with this, as we show reduced effector T cells and cytokines, and a preserved Foxp3hi Treg population .
SIT with depigmented-polymerised extracts, which have at least 95% reduced IgE binding compared to native allergen extract, has been shown to be clinically effective in reducing symptom scores for rhinoconjunctivitis and asthma with minimal side effects and rapid up-dosing [5–8]. Further studies are required to examine the effects of Depig-pol extracts on Tregs in vivo, and to determine whether 1α, 25-dihydroxyvitamin D3 can enhance tolerance in a clinical setting of SIT.
Depigmented-polymerised allergen extracts appear to favour Treg expansion over activation of effector T cells to a greater extent than unmodified allergen extracts. 1α, 25-dihydroxyvitamin D3 further reduces effector T cell activation by both allergen extracts, and may be a useful adjuvant for SIT.
Volunteers and peripheral blood mononuclear cell (PBMC) culture
Atopic allergic volunteers were sensitized to both grass pollen and house dust mite (by skin prick tests and/or specific IgE). Clinical details are shown in Table 1. All had persistent AR and in 3 cases asthma. None was treated with systemic corticosteroids and all had stable disease controlled with topical treatment only. None of the volunteers had received immunotherapy. The study was approved by Guy’s Hospital Ethics Committee and all volunteers gave written consent. Skin prick tests were performed using Soluprick (ALK Horsholm, Denmark) and specific IgE was measured using immunoCAP (Phadia, Uppsala, Sweden). PBMC were separated by Lymphoprep density centrifugation (Axis-Shield, Oslo, Norway), then cultured in RPMI 1640 media with L-glutamine, gentamicin (all from Invitrogen, Paisley, UK), and 5% AB human serum (PAA, Pasching, Austria) in triplicate in 96 well plates at 2×106 cells/ml for 7 days with a range of concentrations of allergen extracts or medium alone in a 5%CO2 incubator at 37°C. Proliferation was assessed by incorporation of titrated thymidine (1 μCi; added 16 hours before analysis) and cytokine production by cytometric bead array (BD Biosciences, Oxford UK). Depigmented-polymerised Phleum pratense (Timothy grass) pollen and Dermatophagoides pteronyssinus (house dust mite, HDM) extracts were compared with native, unmodified allergen extracts, and initially with depigmented non-polymerised extracts (all prepared as described by Laboratorios Leti, Tres Cantos, Spain, 4).
Assessment of regulatory and effector cells in culture and effect of 1α, 25 hydroxyvitamin D3 Flow cytometry was used to examine the relative numbers of T cells with regulatory or effector phenotype after 7 days culture as previously described  (CD4+CD25hiCD127loFoxp3hi for regulatory T cells, and CD4+CD127+CD25+Foxp3lo for effector T cells). All antibodies were from BD Biosciences (Oxford, UK) except that for Foxp3, which was from EBiosciences (Hatfield, UK). We have previously used this gating strategy to identify regulatory T cells after culture, and confirmed suppressive activity of these cells by re-culture of sorted cells . We added 1α, 25-dihydroxyvitamin D3 (BIOMOL Research Labs, Plymouth Meeting PA, USA) to further cultures of PBMC from atopic donors with both depigmented-polymerised and native allergen extracts. Pilot experiments showed the optimal dose of 1α, 25-dihydroxyvitamin D3 for expansion of Foxp3+ T cells to be 10-7 M in this culture system (data not shown).
Data for proliferation and cytokine production was compared by ANOVA for dose response data for native and Depig-pol extracts. Values for regulatory/effector cell ratios and cytokines were compared by paired or unpaired t-test or Mann Whitney U/Wilcoxon tests as appropriate after testing for normality of distribution. All statistics were performed using GraphPad Prism (La Jolla, CA, USA).
This study was funded by Laboratorios Leti, Spain, including salary support for ZLU. MEM and JC are paid employees of Laboratorios Leti, Spain, and DSR is a paid consultant to Laboratorios Leti. CB was supported by the National Institute for Health Research (NIHR) Clinical Research Facility at Guy’s & St Thomas’ NHS Foundation Trust and NIHR Biomedical Research Centre based at Guy’s & St Thomas’ NHS Foundation Trust and King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department for Health. We gratefully acknowledge the support of the divisional research nurses, Mrs Kheem Jones and Mrs Cherylin Reinholtz.
- Bousquet J, Lockey R, Maling HJ: Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO Position paper. J Allergy Clin Immunol. 1998, 102: 558-562. 10.1016/S0091-6749(98)70271-4.PubMedView Article
- Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E: Standards for practical allergen-specific immunotherapy. Allergy. 2006, 61 (Suppl 82): 1-20.PubMedView Article
- Grammer LC, Shaughnessy MA, Patterson R: Modified forms of allergen immunotherapy. J Allergy Clin Immunol. 1985, 76: 397-401. 10.1016/0091-6749(85)90661-X.PubMedView Article
- Casanovas M, Gómez MJ, Carnés J, Fernández-Caldas E: Skin tests with native, depigmented and glutaraldehyde polymerized allergen extracts. J Investig Allergol Clin Immunol. 2005, 15: 30-36.PubMed
- Pfaar O, Robinson DS, Sager A, Emuzyte R: Immunotherapy with depigmented-polymerized mixed tree pollen extract: a clinical trial and responder analysis. Allergy. 2010, 65: 1614-1621. 10.1111/j.1398-9995.2010.02413.x.PubMedView Article
- Höiby AS, Strand V, Robinson DS, Sager A, Rak S: Efficacy, safety, and immunological effects of a 2-year immunotherapy with Depigoid birch pollen extract: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy. 2010, 40: 1062-1070. 10.1111/j.1365-2222.2010.03521.x.PubMedView Article
- Pfaar O, Urry Z, Robinson DS, Sager A, Richards D, Hawrylowicz CM, Bräutigam M, Klimek L: A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy. Allergy. 2012, 67 (2): 272-279. 10.1111/j.1398-9995.2011.02736.x.PubMedView Article
- Garcia-Robaina JC, Sanchez I, de la Torre F, Fernandez-Caldas E, Casanovas M: Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study. J Allergy Clin Immunol. 2006, 118: 1026-1032. 10.1016/j.jaci.2006.07.043.PubMedView Article
- Pfaar O, Klimek L, Sager A, Bräutigam M: Safety of a depigmented, polymerized vaccine for the treatment of allergic rhinoconjunctivitis and allergic asthma. Am J Rhinol Allergy. 2010, 24: 220-225. 10.2500/ajra.2010.24.3437.PubMedView Article
- Carnés J, Himly M, Gallego M, Iraola V, Robinson DS, Fernández-Caldas E, Briza P: Detection of allergen composition and in vivo immunogenicity of depigmented allergoids of Betula alba. Clin Exp Allergy. 2009, 39: 426-434. 10.1111/j.1365-2222.2008.03132.x.PubMedView Article
- Gallego MT, Iraola V, Himly M, Robinson DS, Badiola C, García-Robaina JC, Briza P, Carnés J: Depigmented and polymerised house dust mite allergoid: allergen content, induction of IgG4 and clinical response. Int Arch Allergy Immunol. 2010, 153: 61-69. 10.1159/000301580.PubMedView Article
- Lund L, Henmar H, Würtzen PA, Lund G, Hjortskov N, Larsen JN: Comparison of allergenicity and immunogenicity of an intact allergen vaccine and commercially available allergoid products for birch pollen immunotherapy. Clin Exp Allergy. 2007, 37: 564-71.32. 10.1111/j.1365-2222.2007.02687.x.PubMedView Article
- Dormann D, Ebner C, Jarman ER, Montermann E, Kraft D, Reske-Kunz AB: Responses of human birch pollen allergen-reactive T cells to chemically modified allergens (allergoids). Clin Exp Allergy. 1998, 28: 1374-1383. 10.1046/j.1365-2222.1998.00407.x.PubMedView Article
- Kahlert H, Stuwe H-T, Cromwell O, Fiebig H: Reactivity of T cells with grass pollen allergen extract and allergoid. Int Arch Allergy Immunol. 1999, 120: 146-157. 10.1159/000024233.View Article
- Kahlert H, Grage-Griebenow E, Stüwe HT, Cromwell O, Fiebig H: T cell reactivity with allergoids: influence of the type of APC. J Immunol. 2000, 165: 1807-1815. 10.4049/jimmunol.165.4.1807.PubMedView Article
- Kalinski P, Lebre MC, Kramer D, De Jong EC, Van Schijndel JW, Kapsenberg ML: Analysis of the CD4+ T cell responses to house dust mite allergoid. Allergy. 2003, 58: 648-656. 10.1034/j.1398-9995.2003.00240.x.PubMedView Article
- Akdis CA, Akdis M: Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2011, 127: 18-27. 10.1016/j.jaci.2010.11.030.PubMedView Article
- Urry Z, Xystrakis E, Richards DF, McDonald J, Sattar Z, Cousins DJ, Corrigan CJ, Hickman E, Brown Z, Hawrylowicz CM: Ligation of TLR9 induced on human IL-10-secreting Tregs by 1alpha,25-dihydroxyvitamin D3 abrogates regulatory function. J Clin Invest. 2009, 119 (2): 387-398.PubMedPubMed Central
- Chambers ES, Nanzer AM, Richards DF, Ryanna K, Freeman AT, Timms PM, Martineau AR, Griffiths CJ, Corrigan CJ, Hawrylowicz CM: Serum 25-dihydroxyvitamin D levels correlate with CD4 (+) Foxp3 (+) T-cell numbers in moderate/severe asthma. J Allergy Clin Immunol. 2012, 130 (2): 542-544. 10.1016/j.jaci.2012.04.022.PubMedView Article
- Urry ZL, Chambers ES, Xystrakis E, Dimeloe S, Richards DF, Gabryšová L, Christensen J, Gupta A, Saglani S, Bush A, O'Garra A, Brown Z, Hawrylowicz CM: The role of 1α, 25-dihydroxyvitamin D3 and cytokines in the promotion of distinct Foxp3+ and IL-10+ CD4+ T cells. Eur J Immunol. 2012, 42 (10): 2697-2708. 10.1002/eji.201242370.PubMedPubMed CentralView Article
- Taher YA, van Esch BC, Hofman GA, Henricks PA, van Oosterhout AJ: 1alpha, 25-dihydroxyvitamin D3 potentiates the beneficial effects of allergen immunotherapy in a mouse model of allergic asthma: role for IL-10 and TGF-beta. J Immunol. 2008, 180: 5211-5221. 10.4049/jimmunol.180.8.5211.PubMedView Article
- Haselden BM, Kay AB, Larché M: Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med. 1999, 189: 1885-1894. 10.1084/jem.189.12.1885.PubMedPubMed CentralView Article
- Campbell JD, Buckland KF, McMillan SJ, Kearley J, Oldfield WL, Stern LJ, Grönlund H, van Hage M, Reynolds CJ, Boyton RJ, Cobbold SP, Kay AB, Altmann DM, Lloyd CM, Larché M: Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med. 2009, 206 (7): 1535-1547. 10.1084/jem.20082901.PubMedPubMed CentralView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.